is just clowning around
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice day so far.
Nice opening.
<bullish>
Northern Dynasty: US Environmental Protection Agency Re-starts Process to Withdraw Obama-era ‘Proposed Determination'
June 26, 2019 Vancouver – Northern Dynasty Minerals Ltd. (TSX: NDM; NYSE American: NAK) ("Northern Dynasty" or the "Company") reports the US Environmental Protection Agency ("EPA") has announced it will re-start the process to withdraw a Proposed Determination initiated by the Obama Administration in 2014 under Section 404(c) of the Clean Water Act ("CWA") in an unprecedented attempt to pre-emptively veto southwest Alaska's Pebble Project before it received an objective, scientific regulatory review under the National Environmental Policy Act ("NEPA").
In May 2017, Northern Dynasty's 100%-owned US subsidiary Pebble Limited Partnership ("Pebble Partnership" or "PLP") entered into a settlement agreement with EPA that allowed the Pebble Project to proceed into normal course permitting under the CWA and NEPA. EPA further agreed to initiate a process to propose to withdraw its Proposed Determination, a process that was subsequently suspended by former EPA Administrator Scott Pruitt in January 2018.
Pebble Partnership CEO Tom Collier said the pre-emptive regulatory action initiated by the Obama-era EPA in 2014 represents a dangerous precedent and poor public policy that threatens investment in responsible resource development throughout the United States.
"The idea that development projects can be vetoed before they are even proposed or a comprehensive, permitting process has been undertaken is one that should not take root in this country," Collier said. "It is wholly inconsistent with the rule of law and a serious deterrent to resource investment and industrial development, and it is for those reasons that we expect the Proposed Determination to be withdrawn by this Administration."
Meanwhile, the Environmental Impact Statement ("EIS") and federal permitting process for Pebble under NEPA being led by the US Army Corps of Engineers (the "Corps") continues to advance. The Corps has published a timeline at www.pebbleprojecteis.com that indicates it expects to finalize the Pebble Project EIS in early 2020 and issue a final Record of Decision by the middle of next year.
"We have every confidence that the Pebble Project as proposed will meet the rigorous environmental standards enforced in Alaska and the US, and that the EIS permitting process now underway will demonstrate that compliance through an open, objective, transparent and science-driven review," Collier said.
About Northern Dynasty Minerals Ltd.
Northern Dynasty is a mineral exploration and development company based in Vancouver, Canada. Northern Dynasty's principal asset, owned through its wholly owned Alaska-based U.S. subsidiary, Pebble Limited Partnership ("PLP"), is a 100% interest in a contiguous block of 2,402 mineral claims in southwest Alaska, including the Pebble deposit. PLP is the proponent of the Pebble Project, an initiative to develop one of the world's most important mineral resources.
For further details on Northern Dynasty and the Pebble Project, please visit the Company's website at www.northerndynastyminerals.com or contact Investor services at (604) 684-6365 or within North America at 1-800-667-2114. Review Canadian public filings at www.sedar.com and US public filings at www.sec.gov.
Ronald W. Thiessen
President & CEO
US Media Contact:
Dan Gagnier
Gagnier Communications
(646) 569-5897
Tune in to KSKA 91.1 FM tomorrow at 10am: Live Q&A with Tom Collier and Rick Halford
A Pebble Invitation
The Pebble Partnership
Talk of Alaska
Tune in to KSKA 91.1 FM or Online at 10am to Listen — Send Your Comments and Questions
The current comment period for the Pebble Mine project ends July 1st. Supporters of the mine say it would bring good jobs to the Bristol Bay region. We’ll discuss the Pebble proposal and take your questions on the next Talk of Alaska.
HOST
Lori Townsend
GUESTS
Tom Collier, CEO, Pebble Limited Partnership
Rick Halford, former Alaska State Senator and Pebble opponent
WHEN
LIVE Broadcast: Tuesday, June 25, 2019 at 10:00 a.m. on APRN stations statewide. Tune in to KSKA 91.1 FM or use the online player.
PARTICIPATE
Call 550-8422 (Anchorage) or 1-800-478-8255 (statewide) during the live broadcast
Learn More at AlaskaPublic.org
To view all of the latest project information — and much more — visit our website.
For more information, contact Mike Heatwole: (907) 339-2600
The Pebble Partnership
3201 C Street, Suite 505
Anchorage, Alaska 99503
You are receiving this email because you have previously expressed interest in the Pebble Project. If you no longer wish to receive updates, please use the Unsubscribe link provided below.
Like
Tweet
Forward
Preferences | Unsubscribe
Nice day so far.
Holding for greener money.
Nice movement the last few days.
<bullish>
<bullish>
<bullish>
<bullish>
Yes TDA shows volume of 400,000
L2 looks thin.
Nice after hours so far.
Amastrong
Heading back up
No one expects the financials to be pretty It just shows they are filing and keeping their word to do it.
Looking good.
Looking good. AVEO
AVEO Oncology to Present at the H.C. Wainwright Global Life Sciences Conference
Source: Business Wire
AVEO Oncology (NASDAQ: AVEO) announced that Michael Bailey, president and chief executive officer, will present at the H.C. Wainwright Global Life Sciences Conference in London on Tuesday, April 9, 2019 at 2:10 p.m. BST.
A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date.
About AVEO
AVEO Pharmaceuticals, Inc. (the “Company” or “AVEO”) is a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs. The Company is working to develop and commercialize its lead candidate tivozanib in North America as a treatment for RCC. The Company has sublicensed tivozanib (FOTIVDA®) for oncological indications in Europe and other territories outside of North America. Tivozanib is approved in the European Union, as well as Norway and Iceland, for the first-line treatment of adult patients with RCC and for adult patients who are vascular endothelial growth factor receptor and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for RCC. The Company also has clinical collaborations to study tivozanib in combination with immune checkpoint inhibitors in RCC and in hepatocellular carcinoma. In addition, a new formulation of tivozanib is in pre-clinical development for the treatment of age-related macular degeneration. As part of the Company’s strategy, the Company has also entered into partnerships to help fund the development and commercialization of its other product candidates. Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, is currently being tested in several investigator sponsored studies jointly funded by the Company and one of its development partners for the potential treatment of squamous cell carcinoma of the head and neck, AML, and pancreatic cancer. The Company’s partner for AV-203, an anti-ErbB3 monoclonal antibody, is planning to initiate clinical studies in China in 2019 in esophageal squamous cell carcinoma and has committed to funding the development of AV-203 through proof-of-concept. The Company has recently regained the rights to AV-380, a humanized IgG1 inhibitory monoclonal antibody targeting growth differentiation factor 15, a divergent member of the TGF-ß family, for the potential treatment of cancer cachexia, and is working to initiate preclinical toxicology studies mid-2019 to support the potential filing of an investigational new drug application with the FDA. The Company is evaluating options for the development of its preclinical AV-353 platform which targets the Notch 3 pathway.
For more information, please visit the Company’s website at www.aveooncology.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Actual results or events could differ materially due to a number of important factors, including risks discussed in the section titled “Risk Factors” in AVEO’s most recent Annual Report on Form 10-K, its quarterly reports on Form 10-Q and its other filings with the SEC. The forward-looking statements in this press release represent AVEO’s views as of the date of this press release. AVEO anticipates that subsequent events and developments may cause its views to change. While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEO’s views as of any date other than the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190402005331/en/
AVEO Contact:
David Pitts, Argot Partners
(212) 600-1902
aveo@argotpartners.com
<bullish>
<bullish>
I added too $AVEO
<bullish>
<bullish>
<beast mode>
<bullish>
<bullish>
<bullish>
<bullish>
<bullish>
Nice day
<bullish>
Agree
<bullish>
<bullish>
180KK
Someone poke it with a stick to see if it moves.
<bullish>